Clinical Trial Update: Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating mobilization and collection of 5×10^6 CD34+ cells/kg in non-Hodgkin's lymphoma patients using a combination of plerixafor plus G-CSF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim (G-CSF) (filgrastim)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Sanofi | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED